Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1089/dna.2020.5703 http://scihub22266oqcxt.onion/10.1089/dna.2020.5703 32716648!ä!32716648 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       DNA+Cell+Biol 2020 ; 39 (10): 1741-1753 Nephropedia Template TP {{tp|p=32716648|t=2020. The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options |pdf=|usr=}}{{32716648}} gab.com Text The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options JO: DNA Cell Biol http://www.kidney.de/pget.php?&tw=1&pmid=32716648 #FOAvip On December 31, 2019, a novel coronavirus, being the third highly infective CoV and named as coronavirus disease 2019 (COVID-19) in the city of Wuhan, was announced by the World Health Organization. COVID-19 has a 2% mortality rate, is known as the third extremely infective CoV infection, and has a mortality rate less than MERS-CoV and SARS-CoV. The CoV family comprises a chief number of positive single-stranded ss (+) RNA viruses that are recognized in mammals. The 2019-nCoV patients showed that the angiotensin-converting enzyme II (ACE2) was the same for SARS-CoV. Structural proteins have an essential role in virus released and budding to various host cells. Notably, evidence indicated human-to-human transmission, along with several exported patients of virus infection worldwide. Nowadays, no licensed antivirals drugs or vaccines for being utilized against these coronavirus infections are recognized. There is an urgent requirement for an extensive research of CoV infections to disclose the route of extension, pathogenesis, and diagnosis and then to recognize the therapeutic targets to facilitate disease control and surveillance. In this article, we present an overview of the common biological criteria of CoVs and explain pathogenesis with a focus on the therapeutic approach to suggest potential goals for treating and monitoring this emerging zoonotic disease. Twit Text FOAVip The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options ????DNA Cell Biol http://www.kidney.de/pget.php?&tw=1&pmid=32716648 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32716648 #FOAvip English Wikipedia <ref>{{Cite pmid|32716648}}</ref> The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options #MMPMID32716648 Asghari A; Naseri M; Safari H; Saboory E; Parsamanesh N DNA Cell Biol 2020[Oct]; 39 (10): 1741-1753 PMID32716648show ga On December 31, 2019, a novel coronavirus, being the third highly infective CoV and named as coronavirus disease 2019 (COVID-19) in the city of Wuhan, was announced by the World Health Organization. COVID-19 has a 2% mortality rate, is known as the third extremely infective CoV infection, and has a mortality rate less than MERS-CoV and SARS-CoV. The CoV family comprises a chief number of positive single-stranded ss (+) RNA viruses that are recognized in mammals. The 2019-nCoV patients showed that the angiotensin-converting enzyme II (ACE2) was the same for SARS-CoV. Structural proteins have an essential role in virus released and budding to various host cells. Notably, evidence indicated human-to-human transmission, along with several exported patients of virus infection worldwide. Nowadays, no licensed antivirals drugs or vaccines for being utilized against these coronavirus infections are recognized. There is an urgent requirement for an extensive research of CoV infections to disclose the route of extension, pathogenesis, and diagnosis and then to recognize the therapeutic targets to facilitate disease control and surveillance. In this article, we present an overview of the common biological criteria of CoVs and explain pathogenesis with a focus on the therapeutic approach to suggest potential goals for treating and monitoring this emerging zoonotic disease. |Animals[MESH] |Antiviral Agents/pharmacology/therapeutic use[MESH] |Betacoronavirus/drug effects/pathogenicity/*physiology[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |Clinical Laboratory Techniques/methods[MESH] |Coronavirus Infections/diagnosis/drug therapy/*virology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/drug therapy/*virology[MESH] |SARS-CoV-2[MESH] |Virus Internalization[MESH]The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and(epmc).pdf DeepDyve Pubget Overpricing